drugset / Trial / NCT01944319

Meropenem Dosage Strategy Based on PPK Model

NCT01944319

Phase 4 Completed 79 enrolled Qingtao Zhou
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the clinical and economical benefits of a meropenem dosage strategy based on a population pharmacokinetic(PPK)-pharmacodynamic(PD) model in lower respiratory tract infection patients.

Timeline

Start
2013-07
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Meropenem Small molecule 1.5 g
Subject Meropenem Small molecule 2 g